Share:
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs ) (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into a distribution agreement with Swixx BioPharma AG ( Swixx ) to be the exclusive distributor of the Company s antibodies, DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in Eastern Europe, including Russia. DANYELZA (naxitamab-gqgk) 40mg/10mL was approved by the U.S. Food and Drug Administration ( FDA ) on November 25, 2020 and is indicated, in combination with granulocyte-macrophage colony-stimulating factor ( GM-CSF ), for the treatment of pediatric patients 1 year of age and older
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA(R) (naxitamab-gqgk) and Omburtamab in Eastern Europe marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Self-collected saliva samples effective for covid diagnosis bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have found that SARS-CoV-2 genetic material can be reliably detected in self-collected saliva samples at a rate similar to that of nasopharyngeal and oropharyngeal swabs.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have found that SARS-CoV-2 genetic material can be reliably detected in self-collected saliva samples at a rate similar to that of nasopharyngeal and oropharyngeal swabs.